The key components of the S.L.A. Pharma strategy to develop and commercialise new products for gastrointestinal disorders are:
- • Working closely with medical institutions and acquiring new opportunities at an early stage of development.
- • Investing in pharmaceutical and clinical development to drive the products forward.
- • Out-licensing products at various stages of clinical development to maximise value in selected markets.
Partnerships are an important component in building on our success and bringing new developments to patients. Current established partnerships cover territories in North, Central and South America, Europe and Australasia. S.L.A. Pharma is seeking partners for various geographic regions and individual countries.